H.R. 1750

119th Congress

In Committee

HEARD Act of 2025

Sponsored byDemocrat:Rep. Strickland, Marilyn [D-WA-10]WA· Introduced 27 February 2025

5

Cosponsors

5

Actions

0

Amendments

0

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

27 February 2025·1 year ago

Summary

Introduced in House · Updated 26 August 2025

Health Equity and Rare Disease Act of 2025 or the HEARD Act of 2025

This bill establishes Department of Health and Human Services (HHS) grants and other initiatives to address rare diseases or conditions (e.g., those affecting less than 200,000 people in the United States) in racial and ethnic minority populations. 

For example, to advance such purposes, the bill establishes within HHS

  • grants to public and private nonprofit entities for data collection and public outreach,
  • grants to health professions schools to improve health care and minority representation in research regarding rare diseases and conditions,
  • grants to tribal epidemiology centers and tribal and urban Indian health centers for research regarding rare diseases and conditions in tribal communities,
  • scholarships and educational loan repayment for medical school students who agree to work as health care professionals serving populations with rare diseases or conditions,
  • initiatives to coordinate research and other activities across the National Institutes of Health, and
  • public health awareness and education campaigns.

Also, the bill requires HHS to submit various reports to Congress on topics including (1) the federal government’s research and public health activities regarding rare diseases or conditions in minority populations, (2) regulatory barriers to treating rare diseases in Medicare beneficiaries of color, and (3) strategies for research and development of treatments for rare diseases or conditions that disproportionately impact minority populations.

Timeline

5 actions

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    27 February 2025 · IntroReferral

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    27 February 2025 · IntroReferral

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    27 February 2025 · IntroReferral

  4. Introduced in House

    27 February 2025 · IntroReferral

  5. Introduced in House

    27 February 2025 · IntroReferral

Sponsorship

5 cosponsors

Cosponsors

  • Democrat5100%

Classification

Policy area

Health

Cosponsor momentum

Cumulative over time

Cosponsors grew from 0 on 27 February 2025 to 5 on 2 September 2025.

Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.